

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>EISEN PAUL</u>  (Last) (First) (Middle) <u>69 CARINDA DRIVE</u>  (Street) <u>GLENHAVEN, C3 2156</u> <u>NSW</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/02/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>RESMED INC [ RMD ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <input type="checkbox"/> <u>Vice President, Europe &amp; Asia</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>ResMed Common Stock</u>	<u>350<sup>(1)</sup></u>	<u>I</u>	<u>Spouse</u>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>ResMed Options</u>	<u>(2)</u>	<u>07/11/2010</u>	<u>ResMed Common Stock</u>	<u>6,000</u>	<u>25.42</u>	<u>D</u>	
<u>ResMed Options</u>	<u>(2)</u>	<u>12/18/2013</u>	<u>ResMed Common Stock</u>	<u>15,000</u>	<u>41.49</u>	<u>D</u>	

**Explanation of Responses:**

- Ownership is held in the form of 3500 CDI's purchased on the Australian Stock Exchange, which is 350 shares of RMD on the NYSE
- Shares vest 1/3 each year with the first 1/3 vesting 1 year after date of grant.

**Remarks:**

Paul Eisen 01/05/2004  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.